Skip to content
NEWSnet Pittsburgh
    • Homepage
Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026

Author: Nested Therapeutics Inc.

Posted Date:

May 24, 2026
  • Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026

    Nested Therapeutics Inc.
    May 24, 2026